Neuphoria Therapeutics Inc. (NEUP) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Neuphoria Therapeutics Inc. (NEUP) Earnings Overview
As of July 8, 2026, Neuphoria Therapeutics Inc. (NEUP) reported trailing twelve-month net income of -$28M, reflecting -130.0% year-over-year growth. The company earned $-5.09 per diluted share over the past four quarters, with a net profit margin of -2.4%.
Looking at the long-term picture, NEUP's historical earnings data spans multiple years. The company achieved its highest annual net income of $3M in fiscal 2014.
Neuphoria Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), INVA ($504M net income, 63.8% margin), PRAX (-$327M net income), NEUP has room to improve margins relative to the peer group. Compare NEUP vs ACAD →
NEUP Earnings vs Peers
Earnings metrics vs comparable public companies
NEUP Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $-369,632 | +98.4% | -$1M | $-0.23 | -2.4% | -7.2% |
| 2024 | -$23M | +27.9% | -$27M | $-0.10 | - | - |
| 2023 | -$32M | -47.9% | -$33M | $-0.17 | - | - |
| 2022 | -$22M | -233.0% | -$21M | $-0.13 | -8253.7% | -8095.2% |
| 2021 | -$7M | -33.6% | -$9M | $-0.10 | - | - |
| 2020 | -$5M | +27.8% | -$6M | $-0.11 | -15255.2% | -19319.3% |
| 2019 | -$7M | +63.3% | -$11M | $-0.16 | -252.8% | -401.6% |
| 2018 | -$18M | -255.3% | -$21M | $-0.46 | -668.3% | -771.8% |
| 2017 | -$5M | +58.2% | -$11M | $-0.13 | -125.6% | -261.5% |
| 2016 | -$12M | +4.6% | -$22M | $-0.33 | -237.8% | -415.7% |
| 2015 | -$13M | -530.6% | -$20M | $-0.37 | -255.7% | -397.5% |
| 2014 | $3M | +133.1% | -$4M | $0.10 | 16.8% | -19.8% |
| 2013 | -$9M | -184.4% | -$18M | $-0.29 | -610.9% | -1222.6% |
| 2012 | -$3M | +67.9% | -$12M | $-0.11 | -278.5% | -1059.8% |
| 2011 | -$10M | -43.2% | -$10M | $-0.37 | -293.9% | -308.1% |
| 2010 | -$7M | -26.0% | -$7M | $-0.28 | -274.4% | -291.3% |
| 2009 | -$6M | -21.0% | -$6M | $-0.27 | -190.1% | -206.4% |
| 2008 | -$5M | +1.0% | -$7M | $-0.24 | -424.9% | -661.7% |
| 2007 | -$5M | -15.4% | -$9M | $-0.31 | -666.8% | -1241.1% |
| 2006 | -$4M | -13.4% | -$6M | $-0.31 | -827.3% | -1177.6% |
| 2005 | -$4M | -41.3% | -$4M | $-0.65 | -1567.3% | -1921.6% |
| 2004 | -$2M | +18.3% | -$3M | $-0.62 | - | - |
| 2003 | -$3M | -55.7% | -$3M | $-0.91 | -441.6% | -384.2% |
| 2002 | -$2M | -17.4% | -$2M | $-0.64 | -216.5% | -188.6% |
| 2001 | -$2M | -97.5% | -$1M | $-0.70 | -279.4% | -195.3% |
| 2000 | $-847,139 | -276.6% | $-540,720 | $-0.69 | - | - |
| 1999 | $-224,963 | - | $-28,704 | $-0.90 | - | - |
Download Data
Export NEUP earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NEUP — Frequently Asked Questions
Quick answers to the most common questions about buying NEUP stock.
What is NEUP earnings per share (EPS)?
NEUP trailing twelve-month (TTM) diluted EPS is $-5.09, reflecting -130.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Neuphoria Therapeutics Inc.'s net income?
Neuphoria Therapeutics Inc. (NEUP) trailing twelve-month net income is $-28M as of 2025. Earnings declined -130.0% year-over-year.
Is NEUP profitable?
NEUP is not currently profitable on a TTM basis, reporting a net loss of $-28M. Net margin is -2.4%. Investors should monitor for a return to profitability.
What is NEUP's earnings growth rate?
NEUP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are NEUP's profit margins?
Neuphoria Therapeutics Inc. net profit margin is -2.4%, operating margin is -7.2%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -1.6%.
Is NEUP growing earnings?
NEUP earnings are declining — EPS fell -130.0% year-over-year. TTM net income dropped to $-28M. This contrasts with the 5-year CAGR of N/A.
What was NEUP's best earnings year?
Neuphoria Therapeutics Inc.'s highest annual net income on record is $3M, achieved in fiscal year 2014. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were NEUP's earnings last quarter?
NEUP's most recent reported quarter was Q3 2026. Net income was $-505063.00 with diluted EPS of $-0.09. For a full breakdown of all quarters, see the quarterly earnings table on this page.